Table 1.
Clinical characteristics of COVID-19 patients included in the study.
| N = 80 | |
|---|---|
| Demographic data | |
| Age, years (mean [SD]) | 54.8 (9.2) |
| Gender, male (n[%]) | 37 (46.3) |
| Birthplace, Spain (n[%]) | 46 (57.5) |
| Medical history | |
| Current smoker (n[%]) | 4 (5.0) |
| Arterial hypertension (n[%]) | 20 (25.0) |
| Diabetes mellitus (n[%]) | 6 (7.5) |
| Dyslipidemia (n[%]) | 21 (26.3) |
| Obesity (n[%]) | 8 (10.0) |
| Chronic respiratory disease (n[%]) | 10 (12.5) |
| Heart disease (n[%]) | 2 (2.5) |
| Clinical data | |
| Time from symptoms onset, days (median [IQR]) | 7.0 (6.0–10.0) |
| Oxygen saturation, % (median [IQR]) | 96 (4) |
| Oxygen saturation < 92% (n[%]) | 6 (8) |
| Chest X-ray, consolidation (n[%]) | 52 (65.0) |
| Severity by WHO (n[%]) | |
| Score 1–2 | 41 (51.3) |
| Score 3 | 15 (18.8) |
| Score ≥ 4 | 24 (30.0) |
| Laboraroty data | |
| Lymphocytes × 103/μL (median [IQR]) | 1.1 (0.8–1.4) |
| Lymphocytes < 0.1 × 103/μL (n[%]) | 29 (36.3) |
| C-reactive protein, mg/dl (median [IQR]) | 6.5 (2.1, 12.0) |
| C-reactive protein > 10 mg/dl (n[%]) | 25 (31.3) |
| D-Dimer, ng/ml (median [IQR]) | 613.0 (364.0, 1036.0) |
| D-Dimer > 500 ng/ml (n[%]) | 48 (60.0) |
| LDH, U/L (median [IQR]) | 615.0 (472.0, 823.0) |
| LDH > 500 U/L (n[%]) | 51 (63.8) |
*SD: standard deviation; IQR: interquartil range; WHO: World Health Organization; LDH: lactate dehydrogenase.